NervGen Pharma
Market cap $211M 107.6M shares (vendor count, Nov 18, 2026) × $1.96 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page
- NVG-291 Ph1 interim2026NVG-291 Ph1 interim, 2026, notable
- NGEN corporate trial startJan 1, 2027NGEN corporate trial start, Jan 1, 2027, routine
- RESTORE Phase 3 corporate update2H 2027RESTORE Phase 3 corporate update, 2H 2027, routine
- NVG-291 Ph3 topline1H 2028NVG-291 Ph3 topline, 1H 2028, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
NVG-300
Discontinued (1)
- NVG-300 — Amyotrophic Lateral Sclerosis · preclinical validation in ALS will not proceed at this time
Capital (as filed)
- Cash
- C$22.1M cash and cash equivalents · Dec 31, 2025 (40-F)
- Operating cash flow
- −C$4.9M annual ÷ 4, year to Dec 31, 2025 (40-F)
- As stated in coverage
- C$61.1M cash, runway 1H 2028 per the update of Sep 25, 2026 — the company's own words as read there, not the filed figure; stated in CAD
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (16)
- 2026-11-17 UPDATE: NervGen Pharma (NGEN) - The Q3 Test: Passed, Not Cleared
- 2026-11-13 UPDATE: NervGen Pharma (NGEN) - The FDA Raises Its Hand 🔒 Paid
- 2026-10-16 UPDATE: NervGen Pharma (NGEN) - The Spreadsheet Confesses 🔒 Paid
- 2026-10-12 UPDATE: NervGen Pharma (NGEN) - The Needle Goes In 🔒 Paid
- 2026-09-25 UPDATE: NervGen Pharma (NGEN) - The Books Get a Do-Over 🔒 Paid
- 2026-08-14 UPDATE: NervGen Pharma (NGEN) — The ATM Went Unused. The Clock Went Long. 🔒 Paid
- 2026-07-02 UPDATE: NervGen Pharma (NGEN) — A $50M ATM Five Weeks After the “Fully Funded” Raise 🔒 Paid
- 2026-05-26 UPDATE: NervGen Pharma (NGEN) — The Gait Data Lands the Day the Deal Closes 🔒 Paid
- 2026-05-22 UPDATE: NervGen Pharma (NGEN) — The Deal Prints. Now You Can See the Cap Table. 🔒 Paid
- 2026-05-21 UPDATE: NervGen Pharma (NGEN) — The Prospectus Hits the Wire
- 2026-05-16 UPDATE: NervGen Pharma (NGEN) — Management Just Put a Date on the Dilution Gap 🔒 Paid
- 2026-04-28 UPDATE: NervGen Pharma (NGEN) — The CFO Watch Item Just Resolved 🔒 Paid
- 2026-04-27 UPDATE: NervGen Pharma (NGEN) - The Sarepta Playbook Worked 🔒 Paid
- 2026-03-07 UPDATE: NervGen (NGEN): Adopting the Sarepta Playbook Ahead of FDA Negotiations 🔒 Paid
- 2026-02-14 UPDATE: NervGen Pharma (NGENF): A C-Suite Shuffle on the Edge of the Dilution Gap
- 2026-01-14 NervGen Pharma (NGENF): Scientific Deep Dive for NVG-291 and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (16 calls)
Every verdict Biotech Distilled has published on NervGen Pharma, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-14 Watch NervGen Pharma (NGENF): Scientific Deep Dive for NVG-291 and Pipeline Products The science is real but the imminent Dilution Gap makes entry premature; wait for the financing overhang to clear or the Phase 3 protocol to be finalized before entering.
- 2026-02-14 Watch UPDATE: NervGen Pharma (NGENF): A C-Suite Shuffle on the Edge of the Dilution Gap C-suite changes (permanent CEO, CFO retirement) do not alter the core thesis; the financing overhang and dilution gap remain, so staying on the sidelines is still warranted.
- 2026-03-07 Watch UPDATE: NervGen (NGEN): Adopting the Sarepta Playbook Ahead of FDA Negotiations Sarepta-playbook hires are a positive signal for a streamlined Phase 3, but the Dilution Gap remains the elephant in the room; wait for the FDA meeting outcome before entering.
- 2026-04-27 Speculative buy speculative UPDATE: NervGen Pharma (NGEN) - The Sarepta Playbook Worked FDA blessed a lean 150-patient Phase 3 protocol, retiring protocol risk and reducing trial cost; the cleanest entry is the morning after the offering prices when dilution is knowable.
- 2026-04-28 Speculative buy speculative UPDATE: NervGen Pharma (NGEN) — The CFO Watch Item Just Resolved Vendola's banker-CFO pedigree (IO Biotech IPO, Rezolute Nasdaq listing) materially lowers the risk of a toxic financing structure, strengthening the post-deal entry thesis.
- 2026-05-16 Speculative buy speculative UPDATE: NervGen Pharma (NGEN) — Management Just Put a Date on the Dilution Gap Management's own going-concern language pegs the runway cliff at Q2 2026, making the imminent deal the defining event; the cleanest entry remains the morning after pricing.
- 2026-05-21 Speculative buy speculative UPDATE: NervGen Pharma (NGEN) — The Prospectus Hits the Wire Leerink/TD Cowen marketed deal with institutional pre-funded warrant demand and Newton Tech gait data in the book looks clean; wait for the final pricing print before entering.
- 2026-05-22 Speculative buy speculative UPDATE: NervGen Pharma (NGEN) — The Deal Prints. Now You Can See the Cap Table. $60M institutional deal at $2.50 with 100% warrant coverage funds RESTORE through LPLV; deal quality is B- but survivable, and the cost basis reset at ~$2.08 offers a workable entry.
- 2026-05-26 Speculative buy speculative UPDATE: NervGen Pharma (NGEN) — The Gait Data Lands the Day the Deal Closes Independent blinded gait analysis showing 10/10 vs 1/10 responders (p=0.0001) and speed-effort dissociation corroborates genuine neural recovery, strengthening the mechanism case at a weaker post-deal price.
- 2026-07-02 Speculative buy speculative UPDATE: NervGen Pharma (NGEN) — A $50M ATM Five Weeks After the "Fully Funded" Raise A fresh $50M ATM five weeks after the 'fully funded' raise suggests the May math was thinner than advertised, but the clinical thesis and institutional deal quality are unchanged; watch ATM utilization on the next 6-K.
- 2026-08-14 Speculative buy speculative UPDATE: NervGen Pharma (NGEN) — The ATM Went Unused. The Clock Went Long. C$86.8M cash with zero ATM shares sold funds RESTORE through the 1H 2028 topline, retiring the going-concern risk, but the timeline is now an 18-month patience trade with no efficacy catalyst before 2028.
- 2026-09-25 Speculative buy speculative UPDATE: NervGen Pharma (NGEN) - The Books Get a Do-Over Non-cash restatement of warrant valuations is a controls red flag but does not affect cash or the RESTORE binary; wait for amended filings before adding to position.
- 2026-10-12 Speculative buy speculative UPDATE: NervGen Pharma (NGEN) - The Needle Goes In RESTORE dosed its first participant on schedule, clearing the top watch-list milestone; readers waiting for proof of trial initiation may now begin gradually building a position on an 18-month horizon.
- 2026-10-16 Speculative buy speculative UPDATE: NervGen Pharma (NGEN) - The Spreadsheet Confesses Restated books confirm an arithmetic volatility-formula error dating to 2020 and a formal material weakness, but cash and the RESTORE binary are unchanged; the ATM is now usable again before the shelf lapses December 25.
- 2026-11-13 Speculative buy speculative UPDATE: NervGen Pharma (NGEN) - The FDA Raises Its Hand FDA Breakthrough Therapy Designation is an independent expert vote of confidence in the CONNECT SCI signal and adds senior FDA engagement, but does not change the n=20-to-n=150 efficacy binary RESTORE must resolve in 2028.
- 2026-11-17 Speculative buy speculative UPDATE: NervGen Pharma (NGEN) - The Q3 Test: Passed, Not Cleared Q3 valuation controls passed their first test without new surprises, but burn accelerated to ~C$13M/quarter and the partial clinical hold is confirmed still active, making the tox package more consequential than previously modeled.
- Long call · opened Apr 27, 2026 at $3.85 · -49.1% vs XBI +9.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (24)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 18, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseNervGen Reports Third Quarter 2026 Financial Results and Provides Business Updatesvia aggregator→ BD updateSummary on the 6-K
- Nov 16, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1→ BD updateNervGen's Q3 2026 financials confirm C$80.1M cash, RESTORE enrollment underway, and the first post-restatement quarter with the new controls in place — but the burn is accelerating and the base shelf expires December 25.
- Nov 12, 2026ReleaseNervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injuryvia aggregator→ BD updateNervGen just secured FDA Breakthrough Therapy Designation for NVG-291 in chronic spinal cord injury — a step above the Fast Track designation already in place, and the most meaningful regulatory de-risking event since the FDA aligned on the RESTORE protocol in April.
- Oct 16, 20266-K/AForeign issuer report (amended) · EX-99.1 EXHIBIT 99.1→ BD updateThe restatement that I flagged with a governance asterisk in September just got its full accounting — two named material weaknesses, a specific remediation roadmap, and confirmation that the books are now clean and cash is untouched. The stock has bled another 8% since RESTORE first-patient-dosed, and the audit picture deserves a clear-eyed update.
- Oct 12, 2026ReleaseNervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injuryvia aggregator→ BD updateRESTORE just dosed its first patient — the milestone I ranked #1 on my watch list has printed, and the 18-month countdown to the binary readout in 1H 2028 officially starts today.
- Sep 25, 2026ReleaseNervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustmentsvia aggregator→ BD updateSummary on the 6-K
- Sep 25, 20266-KForeign issuer report→ BD updateNervGen's Audit Committee just declared every financial statement I've cited since the original deep dive unreliable — the company is restating FY2024, FY2025, and Q2 2026 financials for non-cash accounting errors in stock option and warrant derivative valuations. The "C$86.8M funded through 1H 2028" runway figure that anchored my August verdict now carries an asterisk until the restated numbers land.
- Sep 24, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Sep 9, 2026ReleaseNervGen to Host Inaugural R&D Day on September 30, 2026
- Aug 13, 2026ReleaseNervGen Reports Second Quarter 2026 Financial Results and Provides Business UpdatesBD extracted 1 program update from this document → NGEN pipeline
- Aug 13, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Jul 2, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Jun 1, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- May 26, 2026ReleaseNervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
- May 26, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- May 22, 2026ReleaseNervGen Announces Pricing of US$60.0 Million Public Offering of Securities
- May 22, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- May 21, 2026ReleaseNervGen Announces Proposed Public Offering of Securities
- May 18, 2026ReleaseNervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
- May 18, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- May 15, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Apr 27, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
- Mar 31, 202640-FAnnual report (Canadian)
- Mar 13, 20266-KForeign issuer report · EX-99.1 EXHIBIT 99.1
9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Oct 16, 202640-F/A40-F/A→ BD updateSummary on the 6-K/A
- Jul 2, 2026SUPPLSUPPL
- May 26, 2026SUPPLSUPPL
- May 26, 2026F-XF-X
- May 26, 2026F-10F-10
- May 26, 2026EFFECTRegistration effective
- May 22, 2026SUPPLSUPPL
- May 21, 2026SUPPLSUPPL
- May 7, 2026S-8Employee plan registration